ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2017
A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Effect of comorbidities on healthcare expenditures for patients on kidney replacement therapy considering the treatment modality and duration in a French cohort.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Twenty years of the French Renal Epidemiology and Information Network.Clinical kidney journal · 2024Article
- Women's Access to Kidney Transplantation in France: A Mixed Methods Research Protocol.International journal of environmental research and public health · 2022Article
- Incremental and Personalized Hemodialysis Start: A New Standard of Care.Kidney international reports · 2022Article
- Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity.World journal of nephrology · 2022Review
- What does the French REIN registry tell us about Stage 4-5 CKD care in older adults?Frontiers in nephrology · 2022Review
- Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study.BMJ (Clinical research ed.) · 2021Observational
- Health claims databases used for kidney research around the world.Clinical kidney journal · 2021Review
- Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Article
- Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Review
- Dialysis-Induced Cardiovascular and Multiorgan Morbidity.Kidney international reports · 2020Review
- The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review.PloS one · 2020Article
- Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.PloS one · 2019Article
- Cost Controversies of a "Home Dialysis First" Policy.Canadian journal of kidney health and disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment according to various renal replacement therapy, age, diabetes status, and clinical events.
methodsIn order to estimate the direct costs of all adult ESRD patients, according to (RRT) modality, patient condition, and clinical events, data from the French national health insurance funds were used.
resultsThe mean monthly costs for the 47,862 stable prevalent patients (73 % of the population) varied substantially according to treatment modality (from 7300€ for in-center hemodialysis to 1100€ for a functioning renal graft) and to clinical event (8300€ for the first month of dialysis, 11,000€ for the last month before death, 22,800€ for the first month after renal transplantation). Mean monthly costs varied according to diabetic status and to age to a lesser extent.
conclusionsThese results demonstrate, for the first time in France and in Europe, the importance of a dynamic view of renal care and the bias likely when comparing treatments in cross-sectional studies.
Indexed as
Identifiers
27146313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.